DNLI – denali therapeutics inc. (US:NASDAQ)
Stock Stats
News
Denali Therapeutics (NASDAQ:DNLI) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $32.00 price target on the stock.
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
How Denali's Brain-Targeted ETV Data and FDA Review Will Impact Denali Therapeutics (DNLI) Investors [Yahoo! Finance]
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™ [Yahoo! Finance]
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
Form 144 Denali Therapeutics Inc. Filed by: Ho Carole
Form 144 Denali Therapeutics Inc. Filed by: Ho Carole
Form 144 Denali Therapeutics Inc. Filed by: Ho Carole
Form 4 Denali Therapeutics Inc. For: Jan 06 Filed by: Schuth Alexander O.
Form 4 Denali Therapeutics Inc. For: Jan 06 Filed by: Watts Ryan J.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.